药石科技(300725) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 reached ¥285,807,823.32, representing a 67.55% increase compared to ¥170,584,228.47 in the same period last year[8] - Net profit attributable to shareholders was ¥69,771,989.47, a significant increase of 147.31% from ¥28,212,630.51 in the previous year[8] - The net profit after deducting non-recurring gains and losses was ¥64,659,819.15, up 152.22% from ¥25,636,226.95 year-on-year[8] - Basic earnings per share were ¥0.45, a 136.84% increase from ¥0.19 in the previous year[8] - The company achieved operating revenue of CNY 285.81 million, a 67.55% increase compared to the same period last year[24] - The net profit attributable to shareholders reached CNY 69.77 million, reflecting a 147.31% year-on-year growth[29] - The company reported a net profit of ¥514,176,007.08 as of March 31, 2021, compared to ¥444,404,017.61 from the previous year, indicating an increase of about 15.7%[68] - Total operating revenue for the first quarter reached ¥285,807,823.32, a significant increase from ¥170,584,228.47 in the previous year, representing a growth of approximately 67.5%[75] - Net profit for the quarter was ¥69,771,813.76, compared to ¥28,212,434.60 in the same period last year, reflecting an increase of approximately 147.5%[81] Cash Flow and Investments - The net cash flow from operating activities was ¥157,685,994.56, showing a remarkable increase of 198.13% compared to ¥52,891,683.93 in the same quarter last year[8] - Cash and cash equivalents decreased by 36.48% to CNY 790.70 million due to increased investment in financial products[24] - The company reported a significant increase in investment income, with current period earnings of approximately ¥2.33 million compared to a loss of ¥1.16 million in the previous period[86] - The total cash outflow from investment activities is approximately ¥1.32 billion, compared to ¥231.96 million in the previous period, indicating a substantial increase in investment activities[97] - Cash flow from financing activities generated a net cash inflow of ¥47,760,000.00, down from ¥65,000,000.00 in the previous period[103] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,530,257,030.14, reflecting a 4.33% increase from ¥2,425,289,638.00 at the end of the previous year[8] - The total amount of short-term borrowings rose by 39.92% to CNY 168.51 million to supplement working capital[24] - Current liabilities totaled ¥496,861,454.22, slightly up from ¥475,938,909.59, indicating an increase of approximately 4.0%[65] - The total liabilities amounted to ¥555,300,191.20, compared to ¥530,568,842.44, reflecting an increase of about 4.7%[65] - The total non-current assets reached ¥612,348,167.93, up from ¥552,071,109.77, which is an increase of approximately 10.9%[62] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,563[12] - The largest shareholder, Yang Minmin, holds 20.68% of the shares, with a total of 31,774,630 shares[12] Research and Development - The company increased its R&D expenses by 73.18% to CNY 29.42 million, emphasizing its commitment to innovation[24] - Research and development expenses were ¥29,415,589.37, which is an increase from ¥16,985,603.04, showing a growth of about 73.4% year-over-year[78] - The company plans to focus on small molecule drugs over the next three years, enhancing R&D investment and integrating resources[29] Risk Management - The company plans to closely monitor regulatory changes in the pharmaceutical industry to mitigate risks associated with policy shifts[35] - The company is exposed to foreign exchange risks due to a high proportion of sales in foreign currencies, particularly USD[37] - The company has established a comprehensive quality management system to address potential quality control risks as it scales operations[39] Environmental and Social Responsibility - The company emphasizes environmental protection and safety in production, investing in facilities to manage waste and ensure compliance[36]